Skeletal Muscle Differentiation and Fusion Are Regulated by the BAR-containing Rho-GTPase-activating Protein (Rho-GAP), GRAF1 by Doherty, Jason T. et al.
Skeletal Muscle Differentiation and Fusion Are Regulated by
the BAR-containing Rho-GTPase-activating Protein
(Rho-GAP), GRAF1*□S
Received for publication, March 23, 2011, and in revised form, May 23, 2011 Published, JBC Papers in Press, May 26, 2011, DOI 10.1074/jbc.M111.243030
Jason T. Doherty‡1, Kaitlin C. Lenhart‡2, Morgan V. Cameron‡, Christopher P. Mack‡§, Frank L. Conlon§¶,
and Joan M. Taylor‡§3
From the Departments of ‡Pathology and Laboratory Medicine, ¶Biology, and Genetics, §McAllister Heart Institute, University of
North Carolina, Chapel Hill, North Carolina 27599
Although RhoA activity is necessary for promoting myogenic
mesenchymal stem cell fates, recent studies in cultured cells
suggest that down-regulation of RhoA activity in specifiedmyo-
blasts is required for subsequent differentiation and myotube
formation. However, whether this phenomenon occurs in vivo
and which Rho modifiers control these later events remain
unclear. We found that expression of the Rho-GTPase-activat-
ing protein, GRAF1, was transiently up-regulated during myo-
genesis, and studies in C2C12 cells revealed that GRAF1 is nec-
essary and sufficient for mediating RhoA down-regulation and
inducingmuscle differentiation.Moreover, forced expression of
GRAF1 in pre-differentiated myoblasts drives robust muscle
fusion by a process that requires GTPase-activating protein-de-
pendent actin remodeling and BAR-dependent membrane
binding or sculpting. Moreover, morpholino-based knockdown
studies in Xenopus laevis determined that GRAF1 expression is
critical for muscle development. GRAF1-depleted embryos
exhibited elevated RhoA activity and defective myofibrillogen-
esis that resulted in progressive muscle degeneration, defective
motility, and embryonic lethality. Our results are the first to
identify a GTPase-activating protein that regulatesmusclemat-
uration and to highlight the functional importance of BAR
domains in myotube formation.
Skeletal muscle development is a tightly regulated process
involving the specification ofmesodermal precursors intomyo-
blasts and subsequent differentiation and fusion of these cells
into multinucleated myotubes. Primary myogenesis is initiated
in somites via the spatial and temporal expression of myogenic
regulatory factors that include MyoD and Myf5, which are
required for initial specification of skeletalmyoblasts, andmyo-
genin, MRF4, and myocyte-specific enhancer factors (MEF2a
and MEF2c), which induce differentiation of these specified
cells. Additional transcriptional control of skeletal muscle dif-
ferentiation is imparted by serum-response factor, a MADS
box-containing transcription factor that promotes both myo-
blast proliferation and expression of skeletal muscle marker
genes (for review see Ref. 1).
It is not completely clear how thesemyogenic regulatory fac-
tors are activated during development, but it is known that the
small GTPase Rho (which can induce serum-response factor-
dependent gene transcription) plays a role. RhoA was reported
to both promote and interfere with the skeletal muscle differ-
entiation program (for review seeRef. 2). However,more recent
studies in cultured cells suggest that RhoA activity must be
tightly regulated in a finely coordinated time-dependent man-
ner to ensure appropriate skeletalmuscle formation (3–5). Spe-
cifically, these later studies showed that although RhoA activity
is necessary for specification of myoblasts, down-regulation of
RhoA activity in specified myoblasts is essential for subsequent
cell cycle withdrawal, expression of skeletal muscle differentia-
tion genes, and myotube fusion (i.e. secondary myogenesis).
The mechanism by which down-regulation of Rho promotes
skeletal muscle differentiation appears to be due to the fact that
RhoA-dependent activation of MRTF-A in proliferating myo-
blasts induces the expression of the transcriptional inhibitor,
Id3. Id3, which has a helix-loop-helix domain but lacks a DNA
binding domain, blocks the function of myogenic regulatory
factors by forming transcriptionally inactive complexes or by
competing for E protein binding (6). Importantly, Iwasaki et al.
(4) found that depletion of Id3 in proliferating C2C12 cells
induced terminal differentiation.
Secondary myogenesis occurs through the fusion of singly
nucleated myoblasts into multinucleated myotubes, a process
that also requires down-regulation of RhoA (3). Although a
complete understanding of the mechanisms governing skeletal
muscle fusion is lacking, it is clear that dramatic reorganization
of the cytoskeleton occurs during this dynamic process (7). In
particular, previous studies have revealed that the formation
and subsequent dissolution of an F-actin focus at the distal ends
of fusion-competentmyoblasts are essential formyoblast-myo-
blast fusion (8). Thus, tight control of Rho-dependent actin
dynamics is likely important for this process.
Small GTPase activity is regulated by factors that facilitate
the transition between an active GTP-bound state and an inac-
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tive GDP-bound state. Restricted expression and subcellular
localization of guanine nucleotide exchange proteins and
GTPase-activating proteins (GAPs)4 are thought to be impor-
tant for precise spatial-temporal activation and inactivation of
specific small GTPases (9). Previous studies have shown that
p190B Rho-GAP expression in mesenchymal cells favors adi-
pocyte specification over myogenic specification (10). How-
ever, to date, no Rho-GAPs have been identified that regulate
muscle maturation. We previously cloned and characterized a
multidomain containing Rho-specific GAP termed GRAF1.
Interestingly, we found that GRAF1 associates with focal adhe-
sion kinase (FAK) through an SH3 domain protein-protein
interaction (11–13). Because FAK (a critical mediator ofmatrix
and growth factor-dependent signaling), like Rho, has also been
implicated in regulating muscle development (14–17), we rea-
soned that GRAF1might serve as a key regulator of RhoA activ-
ity during myogenesis.
Using cultured mammalian myoblasts, we established that
GRAF1 regulates skeletalmuscle differentiation in a Rho-GAP-
dependent and cell-autonomous fashion that requires its SH3
domain. Moreover, we show that GRAF1 expression drives
muscle fusion by a process that requires GAP-dependent actin
remodeling. Interestingly, GRAF1 also contains an amphi-
pathic lipid bending/sculpting BAR domain, and we found that
this domain is also critical forGRAF1-dependentmuscle fusion
in vitro. Furthermore, we show that GRAF1 is a bona fidemod-
ulator of Rho activity in vivo and thatGRAF1depletion inXeno-
pus laevis attenuates muscle maturation and leads to progres-
sive myofiber degeneration. Our results are the first to identify
a Rho-GAP that regulates muscle maturation and to highlight
the functional importance of BAR domains in myotube
formation.
EXPERIMENTAL PROCEDURES
Commercial Antibodies and cDNA Constructs—Antibodies
used were ERK-CT (Upstate), myosin heavy chain (MHC,
Abcam), skeletal -actin (SKA, Sigma), -actinin (Sigma), tro-
ponin T (CT3, Developmental Studies Hybridoma Bank), tro-
pomyosin (CH1, Developmental Studies Hybridoma Bank),
12-101 (Developmental Studies Hybridoma Bank), HNK
(ZN12; Developmental Studies Hybridoma Bank), and p21
(Santa Cruz Biotechnology). Xenopus and human GRAF1
cDNAs were obtained from Open Biosystems and were direc-
tionally subcloned into cDNA3.1-FLAGor pRK5-Myc epitope-
tagged vectors using 5-BamHI and 3-EcoRI restriction
sites that were generated by PCR. Prk5 vectors containing con-
stitutively active RhoA (L63) or dominant-negative RhoA
(N19) were the generous gifts from Alan Hall, University Col-
lege, London, United Kingdom). GAPm, BARm, and BAR
variants were generated by PCR site-directed mutagenesis
using primers that were 5-phosphorylated and HPLC-purified
using standard procedures (QuickChange, Stratagene). To gen-
erate GRAF1loxp, GAPloxp, and BARloxp, L63RhoAloxp and
N19RhoAloxp, the Myc-tagged variants were amplified from
pRK5myc constructs by PCR with primers that incorporated
3- and 5-NotI sites with an internal KpnI site. This fragment
was then ligated into a vector containing a cassette in which a
1700-bp fragment of the -actin promoter was fused to cDNA
containing GFP flanked by loxP sites (18). All constructs that
were generated by PCR were confirmed by sequencing the
entire coding sequence. Ad5CMV Cre adenovirus was pur-
chased from theUniversity of IowaGeneTransfer Vector Core,
and Ad5CMV LacZ adenovirus was purchased the University
of North Carolina Chapel Hill Viral Core. Both viruses were
expanded using Adenopure adenovirus purification kit (Pure-
syn, Inc.) according to manufacturer’s protocol.
Generation of GRAF1 Polyclonal Antibody—Amino acid
sequences of human,mouse, andX. laevisGRAF1were aligned,
and the conserved sequence CGTLNGKTGLIPENYVEFL cor-
responding to the extreme C terminus of GRAF1 was selected
for antibody production. Purified peptides were obtained com-
mercially (Invitrogen), and rabbit polyclonal antibodies were
generated commercially by standard procedures (Cocalico Bio-
logicals). Sera were screened for immunoreactivity byWestern
analysis of lysates generated from COS cells transfected with
plasmids encoding human orXenopusGRAF1 and endogenous
GRAF1 isolated frommouse heart and brain. A consistent band
of the predicted 110-kDa size was also confirmed byWestern
analysis using in vitro translation assays utilizing recombi-
nant human and Xenopus GRAF1 (supplemental Fig. S4, A
and B). GRAF1 often appears as a doublet in skeletal muscle
consistent with our previous studies in isolated cardiomyo-
cytes (12). Although the origin of these two forms is not
currently known, they could arise from either alternative
transcripts or phosphorylation.
Morpholinos, Embryo Culture, and Microinjection—The fol-
lowing morpholinos conjugated to fluorescein isothiocyanate
(FITC), and a standard control morpholino (Con Mo) were
obtained from GeneTools. Sequences used were as follows:
mo1, 5ACGAGATCAGGAAGGCATTGACA3, andmo2, 5
GGTAATCCCATCCTGGCGTATAGCA 3. Five-base mis-
matchedmorpholinos were designed for bothmo1 andmo2 (5
ACcAGATgAGcAAGcCATTcACA 3 and 5 GcTAATgC-
CATgCTGGCcTATAcCA 3) and were used as controls to
assess the specificity of the morphant phenotype. Preparation
and injection of X. laevis embryos was carried out as described
previously (19). Equal concentrations ofmo1 andmo2morpho-
linos (or mis-matched controls) were mixed and injected at a
concentration of 40 ng/embryo at the one-cell stage (see sup-
plemental Fig. S6 for efficacy and specificity of morpholinos).
In Vitro Transcription/Translation Assays—In vitro tran-
scription/translation assays were performed on plasmids
encoding Xenopus GRAF1 and human GRAF1 using the TNT
Quick-coupledTranscription/Translation System according to
the manufacturer’s instructions (Promega).
Whole-mount Immunohistochemistry, TEM, and in Situ
Hybridization—Embryos were prepared for whole-mount
immunohistochemistry or TEMby fixation overnight at 4 °C in
4% or 2% paraformaldehyde plus 2.5% glyceraldehyde, respec-
tively, and processed by standard procedures. In brief, for
4 The abbreviations used are: GAP, GTPase-activating protein; Rho-GAP, Rho-
GTPase-activating protein; TEM, transmission electron microscope; Tm,
tropomyosin; FAK, focal adhesion kinase; LSM, low serum medium; SH3,
Src homology domain 3; Mo, morpholino; Con Mo, control morpholino;
SKA, skeletal -actin.
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immunohistochemistry, paraformaldehyde-fixed embryos
were washed twice in PBS, 1% Triton X-100, 1% DMSO (PBS-
TD) and were blocked for 4 h at room temperature in PBS-TD
containing 0.1 M glycine, 2% powdered milk, and 5% goat
serum. Embryos were photobleached in 5% H2O2 in PBS for at
least 4 h under bright light. Embryos were then rinsed with PBS
and treated with 1 g/ml bovine testicular hyaluronidase in 50
mM sodium acetate buffer for 45 min at room temperature.
Embryos were rinsed, blocked, and incubated overnight at 4 °C
with primary antibodies diluted 1:200 in block buffer. Embryos
were then washed six times (1 h each) in PBS-TD at room tem-
perature and incubated overnight at 4 °C with the appropriate
Cy-3 orAlexa-488 conjugated secondary antibodies (1:250) and
ToPro3 (1:1000) to stain nuclei (Molecular Probes). Embryos
were again washed six times (1 h each) in PBS-TD, fixed in
Dent’s fixative, and stored in 100% methanol at 20 °C.
Whole-mount in situ hybridization was performed as
described previously (20). Plasmids for MyoD and xGRAF1
were linearized and used to generate digoxigenin-UTP-labeled
(Roche Applied Science) antisense RNA probes using the
appropriate restriction endonuclease and polymerase. Color
detection was determined by BM Purple substrate (Roche
Applied Science) after incubation with alkaline phosphatase-
conjugated anti-digoxigenin antibody. For cryosectioning,
embryos were incubated overnight at 4 °C in a 30% sucrose
solution in PBS and embedded in Tissue Tek OCT (Sakura
Finetek). Cryosections (14 m) were cut on a Leica cryostat.
For TEM, stage 25 and 37 embryos were fixed in 2% para-
formaldehyde and 2.5% glyceraldehyde overnight at 4 °C.
Embryos were then processed and visualized by TEM as
described previously (21). Briefly, embryos were post-fixed in
ferrocyanide-reduced osmium and embedded in Spurr’s epoxy
resin. Parasagittal ultra-thin (70 nm) sections weremounted on
copper grids and post-stained with 4% aqueous uranyl acetate
followed by Reynold’s lead citrate. Sections were imaged with a
LEO EM-910 transmission electron microscope.
Microscopy and Image Deconvolution—Embryos were
cleared for microscopic analysis in 2:1 benzyl benzoate/benzyl
alcohol and placed on a glass coverslip. Embryos or cells were
analyzed by wide field microscopy using a Leica MZFLIII fluo-
rescence dissecting scope or Olympus IX81 microscope or by
confocal microscopy using an Olympus FV500 laser-scanning
confocal microscope. Images were acquired using a Cool-
SNAPfx CCD camera (Photometrics) and analyzed by ISEE,
AMARIS, or Fluoview version 5.1 software. Confocal Z-stacks
were obtained using a 1.24-m step size. Z-series stacks were
deconvolved using Autodeblur Gold version X.1.4.1 software
(Autoquant, Media Cybernetics). RGB image overlays were
performed using Adobe Photoshop.
Cell Culture, Transfection, and siRNA Treatment—The
C2C12mouse andL6 ratmyoblast cell lineswere obtained from
ATCC and cultured at subconfluent density in growth media
(G) consisting of Dulbecco’smodified Eagle’smedia 10% FBS
 penicillin/streptomycin. For differentiation, myoblasts were
plated on slides or dishes pre-coated with rat tail collagen (10
g/ml) and transferred to low serum media (LSM) containing
2% horse serum. Cells maintained in growth media were
transfected with cDNAs using Trans-IT (Mirus) transfection
reagents according to the manufacturer’s protocol. Cells were
infected with Cre or LacZ adenoviruses at 100 multiplicities of
infection.
Short interfering RNA (siRNA) oligonucleotides were
obtained from Invitrogen with the following sequences:
GCAGCUGUUGGCCUAUAAU(dT)(dT) and AUUAUAG-
GCCAACAGCUGC. C2C12 cells maintained in growth condi-
tions (10% FCS) were transfected with 150 nM control or
GRAF1-specific siRNAs according to the manufacturer’s spec-
ifications using Dharmafect 1. After 8 h, C2C12 cells were
exposed to low serum media (containing 2% horse serum) for
the indicated times.When transfected alone, each siRNA led to
significant GRAF1 depletion (and reduced induction of MHC),
but combined treatment with 75 nM each led to a more pro-
nounced reduction (data not shown) and was used in the data
sets shown in Fig. 3.
Immunocytochemistry—Immunofluorescent staining of 4%
paraformaldehyde-fixed cells was performed by standard pro-
cedures. Cells were incubated with primary antibodies at a
1:1000 dilution or with Texas Red phalloidin (1:1000) to visu-
alize filamentous actin for 1 h at room temperature followed by
1 h of incubation with appropriate fluorescent secondary
antibody.
Western Blotting—Embryos (n  5–10) were snap-frozen in
liquid nitrogen, and protein lysates were generated by brief
(1–2 s) sonication in a modified RIPA buffer (10 mM Tris, pH
7.5, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20 mM Na4P2O7,
1% Triton X-100 plus a mixture of protease and phosphatase
inhibitors, including 1 mM Na3VO4, 40 mM NaF, 10 mM Na2
pyrophosphate, 100 M leupeptin, 1 mM 4-(2-aminoethyl)ben-
zenesulfonyl fluoride hydrochloride, 0.02 mg/ml soybean tryp-
sin inhibitor, and 0.05 trypsin inhibitory units/ml aprotinin).
C2C12 or L6 cells were lysed directly in the RIPA buffer con-
taining inhibitors. Fifty micrograms of clarified protein lysate
was separated by SDS-PAGE, transferred onto nitrocellulose,
and processed for Western analysis by standard procedures. In
brief, following transfer to nitrocellulose, membranes were
blocked in 5% dry milk in Tris-buffered saline (TBS)  0.1%
Tween (TBST) and incubated overnight with primary antibody
diluted (1:1000) in blocking solution. Blots were incubatedwith
the appropriate horseradish peroxidase-conjugated secondary
antibodies (1:2000 dilution) (GEHealthcare), and proteinswere
visualized by chemiluminescence (Thermo Scientific).
RT-PCR Analysis—RNA was isolated from 10 embryos fol-
lowing lysis in TRIzol according to the manufacturer’s specifi-
cations (Invitrogen). Reverse transcription reactions were per-
formed using the iScript cDNA kit (Bio-Rad), and PCRs were
performed using ExTaq polymerase (Takara Bio). RT-PCRs
were performed using previously published primer sets and
cycling parameters for x-mhc and x-myogenin (22, 23). Primers
for histone H4 and x-GRAF1 were forward 5 GGG ATA ACA
TTC AGG GTA TC 3 and reverse 5 CAT GGC GGT AAC
TGTCTTC3 and x-GRAF1 forward 5-GCCAGGAGTCAA
GAA TCA AGG 3 and x-GRAF1 reverse 5 CAA CTC CAA
GGT TGG CTA CAG TC 3.
RhoA Activity Assays—One confluent 35-mm dish of L6 or
C2C12 cells/time point or 10 embryos for each treatment (Con
Mo- and GRAF1 Mo-injected) were collected at stage 22, and
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tails were snap-frozen in liquid nitrogen for use in the G-LISA
luminescence-based RhoA-specific activation assay (BK121,
Cytoskeleton). 10 Xenopus tails/time point or one 35-mm dish
of L6 or C2C12 cells were thawed on ice and immediately lysed
in 100 l of ice-cold lysis buffer containing protease inhibitors
(supplied by themanufacturer) by sonication (1-s pulses at 20%
power three times; Sonics VibraCell). Lysates were clarified by
centrifugation (3 min at 4 °C), and RhoA activity was assessed
with a final concentration of 1 mg/ml lysates as per the manu-
facturer’s instructions (Cytoskeleton).
Cdc42Activity Assays—GST-Pak (amino acid 1–290 of Pak1)
was purified from bacterial lysates using glutathione-agarose
beads as described previously (24). In brief, vector or GRAF1-
transfected L6 myoblasts were lysed in Buffer A (50 mM Tris,
pH 7.6, 500 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% Triton
X-100, 0.5 mM MgCl2, plus 100 M leupeptin, 1 mM 4-(2-ami-
noethyl)benzenesulfonyl fluoride hydrochloride, and 0.05 tryp-
sin inhibitory units/ml aprotinin) and cleared by centrifugation
for 10min at 14,000 rpm at 4 °C. 500g of lysate was combined
with 30g ofGST-PAK, and sampleswere rotated at 4 °C for 30
min. The complexes were pelleted by centrifugation and
washed three times in Buffer B (50 mM Tris, pH 7.6, 150 mM
NaCl, 1% Triton X-100, 0.5 mM MgCl2, plus 100 M leupeptin,
1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, and 0.05 tryp-
sin inhibitory units/ml). Samples were boiled in SDS-PAGE
buffer, electrophoresed (15% SDS-polyacrylamide gel), and
transferred to polyvinylidene difluoride (Bio-Rad). Western
blotting was performed using an anti-Cdc42 primary antibody
(Santa Cruz Biotechnology).
Statistical Analysis—Enzymatic assays were measured in
triplicate, and statistical analyses were performed by paired
two-tail t test. Data are expressed as mean  S.E. and were
considered statistically significant at p  0.05. All Western
blots were performed at least three separate times, and repre-
sentative images are shown. Cellular phenotypes were scored
from at least three separate experiments, and data were tabu-
lated from a minimum of 150 cells per treatment group.
RESULTS
GRAF1 Is Expressed in DifferentiatingMyoblasts—Given our
previous findings that GRAF1 was most abundantly expressed
in terminally differentiated cells of adult mammalian tissues
(heart and brain) (12, 13), we predicted that GRAF1-dependent
inhibition of RhoA might play an important role in promoting
cellular differentiation. Interestingly, we recently found that
GRAF1 is transiently expressed at high levels in late embryonic/
early neonatal rodent soleus muscle with peak expression
occurring at post-natal day 4 (P4) when mammalian myoblasts
undergo cell cycle withdrawal, differentiation, and fusion to
form multinucleated myotubes (Fig. 1A) (25). Coupled with
recent findings that down-regulation of RhoA is critical for
myoblast differentiation, we sought to gain further insight into
the relevance of GRAF1 expression during this dynamic pro-
cess. C2C12 and L6 arewell establishedmultipotentmesenchy-
mal progenitor cell lines that undergo spontaneous differenti-
ation into multinucleated skeletal muscle myotubes when
cultured under high confluence in low serummedia (LSM) (26,
27). Western analysis revealed that GRAF1 expression was
markedly induced upon subjecting C2C12 cells to differentiat-
ing conditions (Fig. 1B) and that GRAF expression was
inversely correlated to RhoA activity (Fig. 1C). Interestingly,
immunofluorescent staining revealed that GRAF1 was induced
in a subset of C2C12 cells following exposure to LSM, and dual
labeling with skeletal muscle differentiation markers myoge-
nin, tropomyosin (Tm), ormyosin heavy chain (MHC) revealed
that GRAF1 expression was induced several hours before these
differentiationmarkers (Fig. 2). Similar results were found in L6
myoblasts, although these cells expressed lower levels of the
differentiation marker genes (data not shown).
GRAF1 Is Necessary for Myoblast Differentiation—We gen-
erated siRNAs specific to GRAF1 and transfected these siRNAs
into proliferating C2C12 myoblasts to determine the role of
GRAF1 in myogenic differentiation. Importantly, transfection
with GRAF1 siRNAs led to a marked decrease in GRAF1 pro-
tein levels, and GRAF1-depleted C2C12 cells expressed signif-
icantly lower levels of myogenin, Tm, andMHCupon exposure
to LSM (Fig. 3A). As well, GRAF1-depleted cells exhibited sig-
nificantly higher levels of RhoA activity in comparison with
control siRNA-treated cells (Fig. 3B). Importantly, treatment
withY27632 at the onset of LSM treatment completely restored
MHC expression in GRAF-depleted myoblasts (Fig. 3C). Col-
lectively, these data indicate that GRAF1 promotes skeletal
muscle differentiation by limiting RhoA/ROCK signaling.
FIGURE 1. GRAF1 expression is induced in differentiating myoblasts.
A, Western blot analysis of GRAF1 protein levels in embryonic (E), postnatal
(P), and adult (Ad) rat hind-limb muscle or brain at the indicated time of devel-
opment. B, C2C12 cells maintained in growth (G) media or exposed to differ-
entiation conditions (LSM) for the indicated times were lysed, and cell
extracts were immunoblotted with GRAF1 and tubulin-specific antibodies.
C, C2C12 cells were treated as described in B, and lysates were subjected to an
ELISA-based RhoA activity assay. Data are expressed as average relative light
units (RLU) per time point (n  3).
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FIGURE 2. GRAF1 up-regulation precedes expression of skeletal differentiation markers. C2C12 cells maintained in growth (G) media or exposed to LSM
for the indicated times were fixed and stained with GRAF1 (green) and indicated skeletal muscle differentiation marker (red; Myg (myogenin); Tm (tropomyosin);
MHC (myosin heavy chain)). Nuclei were labeled with DAPI (blue). Scale bar, 50 m. Arrowheads highlight GRAF recruitment to bi-polar tips of differentiated
myoblasts (also see Fig. 7A).
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GRAF1 Promotes Skeletal Muscle Differentiation in a GAP-
dependent Fashion—Because high levels of Rho activity may be
critical for maintaining C2C12 cells in an immature and prolif-
erative state under growth conditions, we next examined
whether ectopic expression of GRAF1 might be sufficient to
promote skeletal muscle marker expression in these cells by
inactivating Rho. Indeed, we found that expression of wild type
FLAG-GRAF1 markedly induced skeletal muscle differentia-
tionmarker expression in C2C12 and L6 cells cultured in either
growth media or LSM as assessed by immunohistochemistry
for skeletal -actin (SKA), MHC, or Tm (Fig. 4, A and B) and
Western analysis for SKA (Fig. 4C). GRAF1-transfected cells
also appeared elongated and spindle shaped, themorphological
features of differentiated myoblasts (7).
To determine whether GAP activity was necessary for
GRAF1-dependent induction of differentiation, we expressed a
GRAF1 variant containing a pointmutation in theGAPdomain
(R412Q) that blocks enzymatic activity (12). Importantly,
transfection with GRAF1 (but not R412QGRAF1; hereafter
referred to as GAPm; Fig. 5A) markedly attenuated RhoA (but
not Cdc42) activity in cultured L6 cells (supplemental Fig. S1,A
and B). As expected, transfection with the GAP-deficient vari-
ant (GAPm) failed to induce skeletal muscle differentiation
marker gene expression of C2C12 cells cultured in growth (data
not shown) or LSM (Fig. 5, B and D). Interestingly, ectopic
expression of the GAP domain alone conferred only partial
activity, indicating that additional functional domains of
GRAF1 are required for its ability to promote myoblast differ-
entiation (Fig. 5D). In support of this idea, we found that a
GRAF1 variant engineeredwith amutation to a conserved tryp-
tophan residue in the SH3 domain (E719Q; referred to as
SH3m), which we previously showed was required for the abil-
ity of GRAF1 to bind FAK and to translocate to focal adhesions,
had a significantly decreased ability to induce differentiation
(assessed by tropomyosin expression) when compared with
wtGRAF1 (Fig. 5D). These data indicate that both GAP activity
and SH3-mediated protein interactions are required for the
optimal induction of the skeletal differentiation program.
Interestingly, GRAF1 but not GAPm induced terminal dif-
ferentiation of C2C12 cells grown in LSM as determined by
marked induction of the cyclin-dependent kinase inhibitor, p21
(amarker of irreversible arrest (28)), and precocious promotion
of multinucleation (Fig. 5C). Indeed, all GRAF1-expressing
FIGURE 3. GRAF depletion attenuates myoblast differentiation by
increasing Rho/ROCK activity. A, C2C12 cells were transfected with control
or a mixture of two GRAF1-specific siRNAs, exposed to LSM for the indicated
times, and cell extracts were immunoblotted with indicated antibody. Tubu-
lin is shown as a loading control. Data are representative of three separate
experiments. B, C2C12 cells were transfected with control or GRAF1-specific
siRNAs and exposed to LSM for 72 h, and RhoA activity was measured an
ELISA-based RhoA activity assay. Data represent the mean  S.D. for three
separate experiments. C, C2C12 cells were transfected with control or a mix-
ture of two GRAF1-specific siRNAs, exposed to LSM with or without the ROCK
inhibitor, Y27632 (10 M), for the indicated times, and cell extracts were
immunoblotted with indicated antibody. Tubulin is shown as a loading con-
trol. Data are representative of three separate experiments.
FIGURE 4. GRAF promotes skeletal muscle differentiation. A and B, C2C12
cells were transfected with FLAG GRAF (F-GRAF) and exposed to either
growth media (A) or LSM (B) for the indicated times. Cells were stained with
anti-FLAG antibody and co-stained with phalloidin and/or the indicated myo-
genic differentiation marker. n  250 –350 cells from 3–5 experiments. Scale
bar, 50 m. C, immunoblots of L6 cells transfected with vector control () or
F-GRAF and exposed to LSM for 24 h. Tub, tubulin.
GRAF1 Promotes Myotube Formation
25908 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 29 • JULY 22, 2011
cells were p21-positive following a 72-h treatment with LSM,
whereas only 12% of vector-treated cells expressed p21 at this
time point. Moreover, nearly 30% of GRAF1-expressing cells
were multinucleated by day 3 of differentiation, whereas nearly
all vector or GAPm-transfected controls remained unfused
(less than 2% were multinucleated). Taken together, these data
demonstrate that expression of GRAF1 promotes cell cycle
withdrawal and terminal differentiation in a Rho-GAP-depen-
dent fashion.
GRAF1 Promotes Myoblast Fusion—Cell fusion occurs
between muscle cells that have undergone early differentiation
events (i.e. expression of contractile proteins), and therefore
GRAF1-dependent enhancement of differentiation alone could
lead to enhanced myotube formation. Thus, to determine
whether GRAF1 can directly impact myotube fusion in pre-
differentiated cells, we expressed Cre-inducible GRAF1 cDNA
variants (hereafter referred to as GRAF1loxp or GAPmloxp; Fig.
6A) to enable time-dependent induction of GRAF1 expression.
Transient transfection of GRAF1loxp and GAPmloxp led to GFP
but not GRAF1 expression in cells treated with LacZ control
virus, but GRAF1 expression was markedly induced in parallel
cultures treated for 24 h with Cre adenovirus (Fig. 6B).
To assess a specific role for GRAF1 in promoting fusion
of differentiated myoblasts, cells were transfected with
GRAF1loxp, transferred to differentiation media for 4 days, and
then treated with Cre or LacZ adenoviruses. As shown in Fig. 6,
C–E, GRAF1-expressing L6 cells (in the Cre-treated cultures)
exhibited a marked increase in myotube fusion in comparison
with nontransfected controls. Although control (LacZ-treated)
transfectants contained up to three nuclei per cell, nearly two-
thirds of GRAF1-expressing cells contained greater than 30
nuclei. Furthermore, the majority of Cre-treated GAPm-ex-
pressing cells (like the Lac Z controls) contained only 1–3
nuclei (Fig. 6,D, bottom, and E). Similar findings were observed
upon GRAF1 expression in pre-differentiated C2C12 cells (see
Fig. 6,C andD). These data confirm thatGRAF1 expression can
promote fusion of differentiated myoblasts in a GAP-depen-
dent manner.
GRAF1 Regulates Actin Organization in Pre-fusedMyoblasts—
Although a complete understanding of the mechanisms gov-
erning skeletal muscle fusion is lacking, it is clear that dramatic
reorganization of the cytoskeleton occurs during this dynamic
process (7). In particular, previous studies have revealed that
the formation and subsequent dissolution of an F-actin focus at
the distal ends of fusion-competent myoblasts are essential for
myoblast-myoblast fusion (8). To determine whether GRAF1
might play an important role in cytoskeletal remodeling that
accompaniesmyoblast fusion,we first examined the subcellular
localization of endogenous GRAF1 in pre-fused myoblasts.
Endogenous GRAF1 localizes to leading edge lamellipodia and
dorsal ruffles as well as a cytoplasmic perinuclear compartment
in myoblasts maintained in growth media (Fig. 2, top left, and
supplemental Fig. S2A). Co-staining with SKA and high power
image merging revealed only a partial overlap between the two
FIGURE 5. GRAF promotes terminal differentiation of myoblasts in a GAP-
and SH3-dependent fashion. A, schematic showing full-length FLAG-
tagged GRAF (F-GRAF) and GRAF variants used herein. PH, pleckstrin homol-
ogy; S/P, serine/proline-rich domain. B and C, C2C12 cells were transfected
with FLAG GRAF1 (F-GRAF) or FLAG GRAF1R412Q (F-GAPm) and exposed to LSM
for 48 (B) or 72 h (C). Cells were stained with anti-FLAG antibody to detect
GRAF variants (green) and co-stained with phalloidin and tropomyosin (Tm) or
p21cip. Scale bars, 50 m. D, quantification of GRAF-induced skeletal differen-
tiation marker gene expression. The number of cells positive for the indicated
marker was counted in control (Con) and GRAF (or indicated GRAF variant-)-
expressing cells exposed to LSM for 48 h. Data represent the % of express-
ing cells counted in three to five separate experiments (n  200 –350
cells/condition).
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proteins, wherein GRAF1 was predominantly localized to the
innermost face of these actin-based structures (supplemental
Fig. S2A). Upon shifting cells to LSM, GRAF1 redistributes to
the bi-polar tips of elongating myoblasts (Fig. 2, middle and
bottompanels, and Fig. 7A). Aswell, co-stainingwith phalloidin
and tropomyosin indicates that these regions are nearly com-
pletely devoid of actin-based structures (Fig. 7A, right).
We reasoned that GRAF1 localization to these discrete sites
may be important for limiting the extent of Rho-dependent
F-actin polymerization. To address this question, we ectopi-
cally expressed F-GRAF1 or GAPm in subconfluent myoblasts
and co-stained with phalloidin to detect filamentous actin.
F-GRAF1 but not GAPm induced marked clearing of actin
stress fibers in myoblasts maintained in serum-containing
media (Fig. 7B). As well, the width of polymerized actin foci was
narrower in GRAF1-expressing cells cultured in LSM than in
nontransfected cells or cells expressingGAPm (Fig. 7,C andD).
Moreover, significant overlay betweenGAPm and polymerized
actin was observed through the entire width of the actin focus,
although the F-GRAF1-labeled region was mostly devoid of
polymerized actin (Fig. 7C, overlay, right panel). From these
data, we surmise that GRAF1 recruitment to the tips of differ-
entiating myoblasts reduces subplasmalemmal actin polymeri-
zation resulting in the dissolution of actin foci and the elonga-
FIGURE 6. GRAF1 promotes fusion of pre-differentiated myoblasts. A, schematic of Cre-inducible Myc-tagged GRAF1 targeting constructs (denoted
GRAF1loxp and GAPmloxp). B, COS cells were transfected with GRAF1loxp or GAPmloxp targeting constructs and treated with Cre () or control, LacZ ()
adenovirus for 24 h. Cells were lysed and immunoblotted with the indicated antibodies. C–E, L6 myoblasts were transfected with GRAF1loxp or GAPmloxp,
exposed to LSM for 4 days to induce differentiation, and transduced with LacZ or Cre adenovirus for 48 h. Dual Myc and DAPI staining revealed marked cell
fusion in GRAF1 (but not GAPm)-expressing cells in comparison with controls. Quantification of cell numbers from three independent experiments is shown
graphically (E, n  150 –250 cells). IF, immunofluorescence. Scale bar, 50 m.
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FIGURE 7. GRAF1 is recruited to a pre-fusion complex and promotes actin-foci dissolution. A, C2C12 cells were exposed to differentiation conditions
(LSM) for 48 h, and endogenous GRAF1 was detected by confocal immunofluorescence microscopy. Note high level of GRAF1 protein localized to the
tips of pre-fused myoblasts. Co-staining with phalloidin to detect filamentous actin or Tm reveals lack of actin-based structures in the GRAF localization
domain (arrowheads). Scale bar, 50 m. B and C, L6 myoblasts transfected with F-GRAF or F-GAPm in growth media or LSM for the indicated time points.
Cells were co-stained with anti-FLAG antibody and phalloidin. Overlay shows high magnification merge of GRAF1 variants and phalloidin. Scale bars, 50
m. D, quantification of areas of actin foci at the leading edge of F-GRAF and F-GAPm cells is shown graphically (n  at least 100 cells/condition from
3 experiments). *, p 0.05.
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tion of pre-fused myoblasts. In support of this theory,
prolonged expression of GRAF1 in subconfluent myoblasts
maintained in growth medium leads to continuous growth of
actin-based filopodial extensions (supplemental Fig. S2B), pos-
sibly due, at least in part, to un-checked activity of Rac- and
Cdc42, as was previously observed in GRAF1-expressing fibro-
blasts (12).
GRAF1-dependent Myotube Formation Requires BAR-medi-
ated Membrane Binding or Sculpting—In addition to the GAP
and SH3 domains, GRAF1 contains a BAR domain that func-
tions to bind and deform plasma membranes and to regulate
endocytosis (29, 30). Because endocytic recycling/trafficking
has been implicated in the merging of membrane bilayers from
two apposing cells during myotube formation (31–34, we rea-
soned that this domainmight also play a critical role inGRAF1-
dependent myoblast fusion. To test this hypothesis, we gener-
ated two GRAF1 variants that either lacked the first 280 amino
acids of GRAF1 that comprise the BAR domain (referred to as
BAR) or that containedmutations in key lysine residues in the
BAR domain (K121E/K131E/K132E) shown previously to
render the protein incapable of lipid bending (referred to as
BARm; see Fig. 8A) (29). Both GRAF1 BAR variants (like
wtGRAF1) induced marked expression of Tm in cells exposed
to LSM for 24 h, indicating that the BAR domain is not neces-
sary for mediating GRAF1-dependent myoblast differentiation
(Fig. 8B). Although the BARmutants appropriately localized to
the bipolar tips of differentiatedmyoblasts (indicated by arrows
in Fig. 8C), the induction of multinucleatedmyotubes observed
at 72 hwas dramatically reduced inBAR- andBARm-express-
ing cells (less than 2%) compared with those expressing wild
typeGRAF1 (33%; Fig. 8C). A similar lack ofmyotube formation
was observed when BARloxp expression was induced in pre-
differentiated C2C12 myoblasts, using the aforementioned
Cre-dependent strategy, despite clearmembrane association of
this variant (Fig. 8, D and E).
GRAF1 BAR mutations have been associated with elevated
GAP activity via relief of auto-inhibition induced by direct
interaction between the BAR and GAP domains (30). Because
previous studies revealed that blocking Rho activity (by expres-
sion of a dominant-interfering mutant, N19RhoA, or by inclu-
sion of the Rho kinase inhibitor, Y27632) enhanced myoblast
fusion (3), one might expect that if the BAR domain was not
essential for myoblast fusion then BARmutants would be even
more effective at promoting fusion than wtGRAF1. Nonethe-
less, additional experiments were performed to ensure that the
inability of GRAF1 BAR variants to induce intercellular fusion
was not due to the elevated GAP activity associated with BAR
mutations. To this end, we generated Cre-inducible constructs
that express dominant-negative (N19) or constitutively active
(L63) RhoA (supplemental Fig. S3A). Using the previously
described experimental paradigm, we examined the ability of
L63RhoA to induce fusion of pre-differentiated myoblasts
when co-expressed with BARloxp. We found that L63RhoA
was incapable of rescuing myotube formation when expressed
over a 30-fold range of concentrations (0.1–3:1 L63RhoA/
BAR, data not shown). We next evaluated whether additional
down-regulation of Rho activity would impair wtGRAF1-de-
pendentmyotube formation.Aswas reported previously (3), we
found that inactivation of Rho (by induced expression of
N19RhoA or by treatment with Y27632) promoted fusion of
pre-differentiated myoblasts (albeit to a lesser extent that
wtGRAF1; supplemental Fig. S3B). Importantly, expression of
N19RhoA or treatment with Y27632 did not impair (indeed
slightly enhanced) the ability of wtGRAF1 to promotemyotube
formation (supplemental Fig. S3C). Thus, the lack of fusion in
the BAR mutants was not secondary to elevated GAP activity
(30). Collectively, these data indicate the following: 1) GRAF1
promotes robust myotube formation in vitro; 2) Rho-GAP
activity is necessary to mediate GRAF1-dependent myoblast
differentiation and fusion; and 3) fusion requires additional
BAR-dependent membrane bending or sculpting.
GRAF1 Is Expressed during Xenopus Somite Development—
We next strove to determine whether GRAF1 is a major regu-
lator of Rho activity and muscle development in vivo. To this
end, we explored the effect of GRAF1 depletion in developing
X. laevis embryos using an antisense-morpholino approach.
Xenopus GRAF1 contains each of the functional domains pre-
viously defined in chicken and mammalian GRAF1, including,
in tandem, a BAR domain, pleckstrin homology domain, GAP
domain, and SH3 domain and the overall amino acid identity of
Xenopus GRAF1 protein to its orthologues in human and
mouse are 83.8 and 77.5%, respectively (NCI-Blast), indicating
that the function of this protein is likely evolutionarily con-
served between these species.
Because Xenopus GRAF1 had not been previously studied,
we first performed semi-quantitative RT-PCR analysis to char-
acterize GRAF1 expression during development. As shown in
Fig. 9A, x.GRAF1 transcript is present at low levels throughout
early development, and expression increases from stage 25
through tadpole stages. To assess the tissue distribution of
GRAF1 in Xenopus, we performed a whole-mount in situ
hybridization analysis of stage 29 embryos using a probe
directed toward the 3UTRof x.GRAF1. In accordancewith our
previous findings in rodents, we observed high levels of
x.GRAF1 expression in the heart and brain (Fig. 9B).
x.GRAF1 was also abundant in the eyes, neural tube, dorsal
root ganglia, and somites (i.e. skeletal muscle precursors,
note segmental pattern; Fig. 9, B and C). As shown in Fig. 9D,
GRAF1 protein levels closely mirrored GRAF1 mRNA levels
during Xenopus development with low levels during gastru-
lation that progressively increased between stages 22 and 37
(see supplemental Fig. S4 for antibody characterization).
GRAF1 was further up-regulated (3-fold) at stage 52, when
intercellular fusion between myoblasts occurs (supplemen-
tal Fig. S5A). Although low levels of GRAF1 were apparent
along the lateral edges of the myofibrils (particularly at early
stages), GRAF1 protein was predominantly localized at the
tips of the myofibers directly adjacent to the myoseptum in
embryos from stage 25 (supplemental Fig. S5B) to 37 (Fig.
9E). This structure, akin to myotendinous junctions in mam-
mals, is the major site of force transmission from myofibrils
across the muscle cell membrane to the extracellular matrix
and underlying skeleton.
GRAF1Depletion Leads to Swimming Defects and Embryonic
Lethality—Injection of GRAF1 morpholinos (GRAF1Mo) that
targeted sequences upstreamof (denotedmo1) and flanking the
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FIGURE 8. GRAF1-dependent myotube fusion requires the BAR domain. A, schematic of GRAF BAR variants. PH, pleckstrin homology; S/P, serine/proline-
rich domain. B and C, C2C12 cells were transfected with F-GRAF, F-BARm, or F-BAR variants, exposed to LSM for 24 or 72 h, and stained as described above.
Tm (red), GRAF1 variant (green), and nuclei (blue). Greater than 95% of GRAF1 and GRAF1 BAR variant expressing cells co-expressed high levels of Tm (n 
150 –200 cells from 3 experiments). Arrows denote appropriate recruitment of BARm to the plasma membrane and presumptive pre-fusion sites. IF, immuno-
fluorescence. D, C2C12 myoblasts were transfected with GRAF1loxp or BARloxp, exposed to LSM for 4 days to induce differentiation, and transduced with LacZ
or Cre adenovirus for 48 h. Quantification of cell numbers from three independent experiments is shown graphically (right panel; n  200 –250 cells). Separate
experiments showed similar results after induction for up to 96 h (data not shown). E, COS cells were transfected with the BARloxp targeting construct and
treated with Cre or control, LacZ adenovirus for 24 h. Cells were lysed and immunoblotted with the indicated antibodies.
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start codon (denoted mo2) of x.GRAF1 at the one-cell stage
markedly reduced embryonic GRAF1 levels at all stages tested
between stage 18 and 37 (Fig. 10A; see supplemental Fig. S6 for
further morpholino characterization). Importantly, GRAF1
immunoreactivity at the myoseptal boundaries was markedly
reduced in stage 37 GRAF1 morphants, further supporting the
specificity of our GRAF1 antibody and our immunofluorescent
methods (supplemental Fig. S6C). Gross morphological assess-
ment of developingConMo- andGRAF1Mo-injected embryos
indicated that gastrulation and neurulation were unperturbed
in the GRAF1 morphants (supplemental Fig. S7A). However,
this finding does not exclude a role for GRAF1 in these pro-
cesses because maternally derived GRAF1 protein (that is not
affected by morpholino injection) is apparent in the GRAF1
morphant embryos through stage 11 (Fig. 10A). However, all
GRAF1 morphant embryos died by the time Con Mo-injected
sibling embryos reached stage 42. By stages 37–39, many
GRAF1 morphant embryos exhibited edema and lateral bend-
ing, and some exhibited diminished anteroposterior axis exten-
sion (Fig 10B and supplemental Table S1). A small percentage
of GRAF1 Mo-injected embryos (2%) arrested during devel-
opment as demonstrated bymarked anteroposterior axis short-
ening and diminished eye pigmentation. These embryos were
not utilized for later analyses.
The most readily observed phenotype in GRAF1 Mo-in-
jected embryos was a fully penetrant and striking swimming
defect (supplemental Table S1 and supplemental movies 1 and
2) that was apparent between stages 35 and 39 (even in embryos
thatwere indistinguishable fromcontrols at a grossmorphological
level). Specifically, whereas ConMo-injected embryos swam nor-
mally in response to touch,GRAF1morphantembryoswereeither
completely unable to swim (49%) or exhibited very limitedmove-
ment of the tail (51%). In addition, the spontaneous swimming
behavior seen incontrol tadpoleswascompletelyabsent inGRAF1
morphant embryos suggesting that the defect was not a defect in
touch response alone. Interestingly, thehearts ofGRAF1-depleted
FIGURE 9. GRAF1 is highly expressed during somitogenesis. A, RT-PCR analysis for x.GRAF1 and histone H4 (H4; loading control) was performed using RNA
isolated from embryos at the indicated stages. B and C, whole-mount in situ hybridization of stage 29 Xenopus embryo using an antisense probe specific for
x.GRAF1: h, heart; b, brain; s, somites; nt, neural tube; drg, dorsal root ganglia. B, lateral view. C, top, transverse; bottom; cross-section through mid-somite region
(somite borders indicated with brackets). D, Western blot analysis of GRAF1 and ERK (loading control) expression at the indicated developmental stages. E, laser
scanning confocal images of whole-mount GRAF1 (red), tropomyosin (green), and ToPro3 (blue nuclei) stained somites from wild type stage 37 embryo. IHC,
immunohistochemistry.
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embryos exhibited normal rhythmic contractions (data not
shown), suggesting the presence of intact functional innervations.
Importantly, injection of 5-bp mismatch morpholinos had no
effect on GRAF1 protein levels or on Xenopus development (data
not shown), indicating that these aforementioned phenotypes
were due to GRAF1 depletion.
FIGURE 10. GRAF1 is essential for maintaining somite architecture and myoseptal boundaries. A, Western blot analysis for GRAF1 in Con MO- and
GRAF1 Mo-injected embryos at the indicated stages of development. IB, immunoblot; St., stain. B, stage 39 GRAF1 Mo-injected embryos exhibit edema
(panel b) and anteroposterior axis defects (panel c) relative to control embryo (panel a). C, laser scanning confocal images of whole-mount stage 30 –37
Con Mo- and GRAF1 Mo-injected somites reveal progressive degeneration. Embryos were stained with Tm or laminin (LAM) to visualize cells or
myosepta, respectively.
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Xenopus GRAF1 Is Necessary for Maintaining Skeletal Mus-
cle Integrity—Laser scanning confocal microscopic analysis of
whole-mount Tm- and laminin-stained stage 30–37 control
and GRAF1 morphant embryos revealed that GRAF1 is neces-
sary formaintaining somite architecture (Fig. 10C). At stage 30,
the organization of Tm-positive cells and the levels and conti-
nuity of laminin at repetitive intersomitic boundary units were
comparable between control and GRAF1 morpholino-injected
embryos (Fig. 10C). However, between stages 32 and 34, all
GRAF1 morphants evaluated exhibited muscle fiber degenera-
tion, and most (87%) had accompanying defects in somite
boundaries. The embryos were categorized as having a mild,
moderate, or severe phenotype using the following scheme:
mild (13%), myofiber splitting or detachment with mainte-
nance of somite boundaries;moderate (51%),myofiber splitting
or detachment accompanied by loss of myoseptal integrity in
up to 30% of the somites; severe (36%), myofiber splitting or
detachment accompanied by disruption of 30% or more somite
boundaries per embryo. Although examples of severe disrup-
tions were found in the all regions of stage 34–37 GRAF1mor-
phant embryos, the middle region was most severely affected.
By stage 37, all (33/33) GRAF1 morphant embryos evaluated
exhibited markedly disrupted myoseptal segmentation (as
demonstrated by the mosaic pattern of laminin staining) likely
due to repair of earlier muscle tears. Collectively, these findings
indicate that GRAF1 depletion leads to progressive somite
degeneration.
To better understand the pathogenesis of muscle deteriora-
tion in the GRAF1morphants, we closely evaluated the somites
of stage 32–34 embryos that exhibited mild or moderate phe-
notypes. As shown in Fig. 11A, these phenotypes were associ-
ated with mid-somite cellular lesions accompanied by retrac-
tion of the cell body (demarcated by Tm, green). Interestingly,
the tips of most cells appeared to remain in contact with the
intersomitic boundary (Fig. 11A, demarcated by LAM, red).
Indeed, ultrastructural analysis by TEM confirmed that the
attachment of the sarcolemma to the intersomitic boundary
was often maintained in GRAF1 morphants (Fig. 11B, middle
panel), indicating that GRAF1 is not necessary for maintaining
adhesion of the muscle fibers to the extracellular matrix-based
myoseptum. However, mid-somite sarcomeric degeneration
was evident (Fig. 11B, right panel) as was complete severing
through terminal sarcomeric units (Fig. 11B, middle panel,
black arrows). In addition, some cells appeared to have dis-
sociated from the myosepta with laminin bound to the
detached cell tips (denoted by asterisk in Fig. 11A, right
panel) indicating that there may be additional defects in
matrix assembly/maintenance.
GRAF1 Depletion Does Not Disrupt Somite Specification,
Somite Rotation, or Boundary Formation—In an effort to define
the preciseGRAF1-dependent step(s) that lead tomyofiber and
myoseptal degeneration, we first assessed whether GRAF1
depletion altered the early specification of the somites. To this
end, we performed whole-mount in situ hybridization analysis
of MyoD that is expressed in a segmental pattern in the pre-
somitic mesoderm of Xenopus from the neurula onward. No
differences in the spatial distribution of MyoD RNA were
observed between Con or GRAF1 MO-injected embryos ana-
lyzed fromstages 18 to 34 (stages 24–34 shown in supplemental
Fig. S7B), suggesting that somites were properly specified in
the absence of GRAF1. In accordance with our in situ anal-
ysis, no significant differences in the levels of MyoD tran-
FIGURE 11. GRAF1 depletion leads to fiber rupture. A, laser scanning confocal microscopy of mildly affected stage 34 somites with Tm (green) and laminin
(LAM) (red) reveal mid-somite tears (denoted by arrows). Laminin association with fiber tip is denoted by an asterisk. Scale bar, 100 m. B, TEM (	2500
magnification) of somite-matched stage 37 Con Mo- and GRAF1 Mo-injected embryos. The myoseptum is denoted by a thick white arrow in the Con Mo panel.
The sarcolemma remained attached to the intersomitic boundary in GRAF1 morphants, but mid-myofiber tears were prevalent (black arrows).
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scripts were observed between ConMo- and GRAF1MO-in-
jected embryos from stages 12.5 to 34 (Fig. 12A), indicating
that dystrophic phenotypes observed in the GRAF1 mor-
phants are not a consequence of defective specification of
the pre-somitic mesoderm.
During Xenopus somitogenesis, somitic cells undergo a 90°
rotation relative to the anteroposterior axis to form parallel
myotome fibers that attach to myosepta (35). To determine
whether this morphogenetic step was altered in the GRAF1
morphants, we next stained stage 25 embryos with ToPro3
(nuclear stain) and a panel of muscle and/or myoseptal bound-
ary markers. Confocal views through the myotome revealed
that GRAF1 morphant embryos contain nuclei that are
arranged in a regularly ordered fashion and are aligned along
the dorsoventral axis at the mid-point of each somite block
(supplemental Fig. S8A), indicating that the GRAF1 morphant
FIGURE 12. GRAF1 morphants exhibit elevated RhoA activity and impaired skeletal muscle differentiation. A, RNA from Con Mo (C)- and GRAF1 Mo
(G)-injected embryos (n  10) was isolated and utilized for semi-quantitative RT-PCR analysis of indicated marker gene. B, lysates from Con Mo- and GRAF1
Mo-injected embryos at the indicated stages were analyzed by Western analysis. Note that the lysates shown in the left panel are identical to those shown in
Fig. 2A. Lysates used for right panel were collected from a separate experiment. IB, immunoblot. C, top, laser scanning confocal microscopy of whole-mount
12–101 (red) and ToPro3 (blue)-stained stage 25 Con Mo- and GRAF1 Mo-injected embryos (scale bar, 500 m). Note appropriate alignment of nuclei but
reduced skeletal muscle differentiation (also see Fig. S3, A and B and Table 1). Bottom, TEM (	2500 magnification) from somite-matched stage 25 Con Mo- and
GRAF1 Mo-injected embryo. Note reduced myofiber content in GRAF1 morphants relative to controls. D, ELISA-based RhoA activity assays were performed on
lysates isolated from stage 22 and 25 Con Mo- and GRAF1 Mo-injected embryos. Ten embryos were processed in batch for each stage and treatment.
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cells completed the 90° rotation that is necessary for subsequent
attachment to themyosepta. Moreover, the levels and continu-
ity of laminin at repetitive intersomitic boundary units were
comparable between control and the majority of GRAF1 mor-
pholino-injected embryos at stage 25 (22/25; supplemental Fig.
S8A and Table 1). Although a small percentage (3/25 GRAF1
morphants) exhibited mild myoseptal disruptions (see supple-
mental Fig. S8B for representative image), co-staining with an
antibody that recognizes the C terminus of -dystroglycan
revealed a continuous overlay of -dystroglycan and laminin in
all control MO and GRAF1 Mo-injected embryos, indicating
that somitic cells are appropriately anchored to the inter-
somitic junctions by stage 25 (supplemental Fig. S8A).
Co-staining with laminin and antibodies that recognize focal
adhesion complex proteins, including paxillin (supplemental
Fig. S8), vinculin, and FAK (data not shown), confirmed that the
GRAF1morphant somitic cells are aligned parallel to the noto-
chord and establish appropriate anchoring to the extracellular
matrix at the intersomitic boundaries. Thus, the initial specifi-
cation, rotation, and attachment of somitic cells to themyosep-
tum appear to be largely unaffected in the GRAF1 morphants.
GRAF1 Is Necessary for Skeletal Muscle Differentiation/Mat-
uration in Developing Tadpoles—Based on our studies in
C2C12 cells, we reasoned that the muscle degeneration pheno-
type might have resulted from impaired skeletal muscle matu-
ration (the next step of somitogenesis). To address this hypoth-
esis, we first analyzed Con Mo- and GRAF1 Mo-injected
embryos by semi-quantitative RT-PCR analysis for the skeletal
muscle differentiation markers, myogenin and skeletal muscle
myosin heavy chain. As shown in Fig. 12A, myogenin andMHC
transcripts were lower inGRAF1-depleted embryos in compar-
ison with the Con Mo-injected controls from stage 18 to 34.
These findings were confirmed by Western blotting of whole-
embryo lysates. GRAF1 depletion led to decreased expression
of all differentiation markers evaluated, including MHC, Tm,
SKA, -actinin, and troponin T (Fig. 12B). Accordingly, dual
labeling of stage 25 embryos with the early skeletal muscle dif-
ferentiation marker 12-101 (36) revealed much lower levels of
skeletal muscle maturation marker in GRAF1 morphant
somites relative to controls (Fig 12C, top panel). Moreover,
using a luminescence-based assay to quantify the GTP-bound
form of RhoA, we found that RhoA activity was significantly
increased inGRAF1MO-injected embryos comparedwithCon
MO-injected embryos at the onset of skeletal muscle differen-
tiation (stages 22 and 25; Fig. 12D). These data confirm our
previous findings that GRAF1 acts as a bona fide Rho-GAP in
vivo and further extends these findings by demonstrating that
GRAF1 serves to down-regulate Rho activity during critical
stages of muscle development.
Ultrastructural analysis by transmission electronmicroscopy
confirmed amarked reduction inmyofiber content as exempli-
fied by more sarcoplasm and less myofibers per myocyte in
GRAF1morphant somites relative to somite-matched controls
at both stage 25 (Fig. 12C, bottom) and 37 (Fig. 11B). Although
repetitive Z-band containing sarcomeres were formed, a lack of
M-bands was apparent, consistent with the marked reduction
of MHC. Thus, we conclude that GRAF plays a critical and
conserved role in promoting muscle fiber maturation and that
the deterioration ofmuscle andmyoseptal boundaries observed
at later stages in theGRAFmorphants is likely due to the inabil-
ity of themalformedmuscle fibers to withstand themechanical
strain imparted on them during subsequent development
and/or induction of motility.
DISCUSSION
Recent studies suggest that down-regulation of RhoA is
required for skeletal muscle differentiation and myotube
fusion; however, little is known about the importance of this
mechanism in vivo or about the molecules that limit RhoA
activity during skeletal muscle development. We show for the
first time that the Rho-specific GAP, GRAF1, is required for
proper skeletal muscle differentiation and sarcomere forma-
tion inX. laevis. Importantly, mammalian GRAF1 is also highly
up-regulated during skeletal muscle maturation, and GRAF1-
dependent down-regulation of Rho activity was necessary and
sufficient for skeletal muscle differentiation in the C2C12
model. Moreover, localization of GRAF1 to cell junctions also
facilitated myoblast fusion into multinucleated myotubes, and
this effect required GRAF1 GAP and BAR domains. Collec-
tively, these data support a cell autonomous and conserved role
for GRAF1 in the control of myogenesis and provide novel
insight into coordinated actin- and membrane-based mecha-
nisms that regulate myotube fusion.
GRAF1 morphant tadpoles exhibited a highly penetrant
swimming defect that was accompanied by disrupted somite
structure, a curved body axis, and lowmotor activity. Although
examples of severe cellular and myoseptal disruptions were
found in all the regions of stage 34–37 GRAF1 morphant
embryos, the middle region was most severely affected. This
phenotype differs from integrin 5 subunit depletion, which
leads to restricted defects in anterior somites (37, 38). Interest-
ingly, disruption of -dystroglycan or integrin-linked kinase in
these species led to similar gross morphological defects and as
those observed in our GRAF1 morphants (39–41). However,
the cause for fiber degeneration is distinct as depletion of integ-
rin-linked kinase resulted in detachment of the intact cell from
the matrix (39), whereas depletion of -dystroglycan led to
detachment within the sarcolemmal membrane plane (40, 41),
and depletion of GRAF1 led to severing of the contractile units.
In some cases, attachment failure in GRAF1 morphants
occurred within the extracellular matrix itself, because laminin
was found to retract into themyotomewith the fiber (similar to
what was observed in zebrafish containing a mutation in the
laminin 2 gene (42)). Although it is difficult to distinguish the
etiology of the matrix defect in the GRAF1 morphants, it is
TABLE 1
GRAF1 depletion leads to progressive somite degeneration
Data represent 25–33 embryos for both control and GRAF morphants per time
point from 4 experiments.
Dystrophic phenotype Stage 25–30 Stage 32–34 Stage 37–39
% % %
Discontinuous boundaries 12 87 100
Muscle tears
Minor 0 13 100
Moderate 0 51 0
Severe 0 36 0
Lack of segmental organization 0 36 100
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possible that initial impairment in the differentiation and ten-
sion generation of themyofibers could lead to impaired integrin
inside-out signaling and subsequent loss ofmatrix cohesiveness
(43, 44). The findings that the initial deposition and organiza-
tion of matrix are normal in the majority of GRAF1 morphants
and that the GRAF1 morphants are capable of remodeling the
laminin matrix to ensure reattachment of presumptive regen-
erating fibers with the myoseptum (apparent in later stage
embryos) indicate that defective myofibrillogenesis is likely the
primary cause ofmyoseptal boundary deterioration observed in
the more severe cases. Thus, we surmise that the lack of appro-
priate myofiber production renders the cells vulnerable to
growth-, contraction-, or twitching-induced mechanical dam-
age to the contractile apparatus, which leads to fiber retraction
and subsequent degeneration of the myoseptal extracellular
matrix. This thesis is consistent with enhanced severity in the
middle of the embryo, which exhibits the most torsion upon
twitching or induction of motility. Although our studies clearly
show that GRAF1 regulates skeletal muscle differentiation, a
role for GRAF1 in regulating myoblast fusion in vivo could not
be assessed in theXenopusmodel, because all GRAFmorphants
died prior to the induction of this process.
There are intriguing similarities, yet some differences be-
tween the reported effects of FAK on somite morphogenesis,
muscle differentiation, and fusion and the effects of GRAF1
reported herein. With respect to somitogenesis, Kragtorp and
Miller (14) reported that ectopic expression of the FAK inhibi-
tor, FRNK, led to early defects in somite rotation associated
with impaired fibronectinmatrix deposition and assembly. Our
data indicate that GRAF1 is expressed at low levels during these
early stages and that GRAF1 depletion does not impair somite
rotation, indicating that FAK likely acts through different tar-
gets to regulate these early events. Indeed, data presented by
Kragtorp andMiller (14) indicate that FAK acts in concert with
Ena/VASP proteins to modulate integrin activity and integrin-
extracellular matrix interactions that are necessary for the
movement of cells prior to alignment with the myoseptum.
Interestingly, recent studies indicate that FAK may also func-
tion to regulate later myogenic processes, because FAK is
required formyogenin expression, terminal differentiation, and
fusion of cultured myoblasts (17, 45). These findings are remi-
niscent of the functions of GRAF1 in these cells and indicate
that GRAF1 may aid to mediate these later FAK-dependent
effects. In support of this possibility, we found that an SH3-
binding mutant of GRAF1 (that fails to interact with FAK)
has a limited capacity to induce skeletal muscle differentia-
tion, indicating that FAK might regulate the appropriate
localization and function of GRAF1. Future studies will fur-
ther address the requirement for the FAK-GRAF1 interac-
tion in muscle development.
Clearly, a complex array of guanine nucleotide exchange pro-
teins andGAPs provides tight control ofGTPase activity during
the many critical stages of muscle development (9). Our report
is the first to demonstrate a role for GRAF1 in the spatial and
temporal down-regulation of Rho during skeletal muscle mat-
uration and fusion. Although no other GAPs have been identi-
fied that regulate muscle maturation, previous studies have
shown that p190B Rho-GAP expression in mesenchymal cells
favors adipocyte specification overmyogenic specification (10).
Although MyoD expression is initiated prior to marked deple-
tion of GRAF1 in our model, the findings that depletion of
GRAF1 from stage 18 onward had no effect on MyoD levels or
localization throughout development and that GRAF1 expres-
sion in mammalian muscle occurs much later than myoblast
specification suggest that GRAF1 does not affect muscle spec-
ification. Thus, these two RhoA-specific GAPs appear to have
nonoverlapping roles during early and late stages of muscle
differentiation, respectively, although it will be important to
further define their expression patterns, cellular localizations,
and overall activity during muscle development.
Our finding that GRAF1 promoted skeletal muscle differen-
tiation is consistent with previous reports demonstrating that
inhibition of Rho/ROCK signaling in differentiating myocytes
promoted expression of skeletal muscle marker genes and
induced terminal differentiation (3, 4). However, these data
seem at odds with the known function of Rho to stimulate the
serum-response factor-dependent expression of many muscle-
specific genes (46) by enhancing the nuclear localization of the
myocardin-related serum-response co-factors. This discrep-
ancymay be explained by the recent demonstration that RhoA-
dependent activation of MRTF-A in proliferating myoblasts
induced the expression of the helix-loop-helix transcriptional
inhibitor, Id3 and that depletion of Id3 in these proliferating
cells induced terminal differentiation (4).
We also found that temporal induction of GRAF1 (but not
GAPm) in pre-differentiated myoblasts inducedmarked fusion
intomultinucleatedmyotubes. Recent elegant time-lapse imag-
ing of fusing myoblasts revealed that pre-fused cells assume a
bipolar shape that is induced by the interaction of nonmuscle
myosin 2A with actin at the plasmamembrane and that a focus
of F-actin appears at the future site of myoblast fusion (7, 47).
The findings that mutations in known fusion genes such as
kette, mbc, and SCAR/WAVE all lead to enlarged F-actin foci
that fail to dissolve indicate that both the formation and subse-
quent dissolution of this actin focus is essential for myoblast
fusion (48, 49). Rho has been shown to initiate actin polymeri-
zation at the onset of the protrusion-retraction cycle, by acti-
vating members of the formin family such as mDia (50, 51).
Thus, we reasoned that GRAF1 might limit Rho-dependent
actin polymerization at sites of myoblast fusion. In support of
this theory, we have shown that GRAF1 localizes to the tips of
pre-fused bipolar myoblasts at the inner face of actin-based
processes, thereby placing its catalytic activity in close proxim-
ity to the actin focus. Moreover, myoblasts in which GRAF1 is
overexpressed exhibitmuch smaller actin foci than control cells
or those expressing GAPm, indicating that GRAF1 promotes
dissolution of the actin focus. Recruitment of GRAF1 from the
perinuclear region (as is observed in proliferatingmyoblasts) to
leading edge protrusions could thus represent a necessary step
for limiting Rho-dependent actin polymerization during myo-
blast fusion.
We also identified a completely novel role for the GRAF1
BAR domain in regulating myoblast fusion. Unlike the GRAF1
GAP domain, which is necessary for both differentiation and
fusion, the BAR domain is only required for myoblast fusion.
We found that the BAR domain of GRAF1 was dispensable for
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recruitment of GRAF1 to the bipolar tips of pre-fused myo-
blasts, suggesting that the BAR domain may mediate a critical
membrane sculpting function. Structural analysis indicates that
BAR domains form elongated homodimers characterized by a
shallow curvature formed by the anti-parallel interaction of two
-helical coils that facilitate membrane deformation (52).
Although our studies are the first to identify a BAR domain-
containing protein as a critical mediator of skeletal muscle
fusion, these lipid bending domains have been previously impli-
cated in both promoting secretory vesicle fission to (and endo-
cytic vesicle budding from) plasma membranes. Indeed, the
GRAF1BARdomain is capable of inducing tubulation of spher-
ical lipids and has been implicated in driving clathrin-inde-
pendent endocytosis in fibroblasts and HeLa cells (29, 30).
Interestingly, other mediators of endocytic membrane recy-
cling, including myoferlin, MG53, and Eps15 homology
domain-containing proteins 1 and 2, have recently been shown
to promotemyoblast fusion (31–33). The presence of unilamel-
lar vesicles observed at sites of myoblast membrane fusion has
been proposed to be important for the recruitment of essential
fusogenic phospholipids and the subsequent internalization of
excess plasma membrane from fusing cells (34). However, to
what extent the specific clathrin-independent/glycosylphos-
phatidylinositol-enriched endocytic compartments that are
regulated byGRAF1might facilitate this process is unknown. It
is also possible that the GRAF1 BAR domain may act in a sim-
ilar fashion to some BAR domain-containing proteins (such as
the related F-BAR containing Rho-GAP, srGAP2) by binding to
the inner neck of the membrane protrusion to induce outward
membrane curvature (53). In fusion-competent cells, such an
event could result in enhanced hydrophobic attractions
between the interiors of the two bilayers, thus promoting lipid
transfer from one membrane to another (54, 55). We have
found thatGRAF1 localizes to the base of dorsal ruffles (circular
ruffles that project up from the plasma membrane; see supple-
mental Fig. S2A) and that ectopic expression of GRAF1 induces
numerous membrane protrusions in myoblasts (see supple-
mental Fig. S2B). Hence, we speculate that in skeletal muscle,
GRAF1 (and perhaps other BAR domain-containing proteins)
might operate to facilitate the initial steps of myotube forma-
tion by bringing membranes from two apposed myoblasts into
direct contact. Whether GRAF1 serves to promote myoblast
fusion by enhancing membrane interactions via membrane
sculpting and/or by regulating endocytic recycling are interest-
ing questions for future studies.
In summary, we provide the first evidence that induction of
skeletalmuscle differentiation is a fundamental GRAF1-depen-
dent process that is conserved across species. The progressive
myofiber degeneration observed in the Xenopus GRAF1 mor-
phants resembles several models of congenic muscular dystro-
phies andhighlights a possible role for persistent Rho activation
in the pathogenesis of this disease. This study also furthers our
understanding of the coordinated control of cytoskeletal and
membrane processes during myotube fusion. The mechanisms
by which GRAF1 or other BAR domain-containing proteins
impact mammalian myotube formation and/or muscle repair
following injury are exciting questions for future study.
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Renkawitz-Pohl, R. (2004) Development 131, 4501–4509
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